Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
Related Posts
Stackpole ML, Zeng W, Li S, Liu CC, Zhou Y, He S, Yeh A, Wang Z, Sun F, Li Q, Yuan Z, Yildirim A, Chen[...]
Shin DS, Basak S, Veena MS, Comin-Anduix B, Bhattacharya A, Dong TS, Ko A, Han P, Jacobs J, Moatamed NA, Avila L, Pellegrini M, Wang[...]
Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry[...]